Pharma M&A trends 2026: Why $1.3tn in firepower is meeting the steepest patent cliff in industry history

Pharmaceutical mergers and acquisitions (M&A) have entered 2026 with the strongest structural tailwinds the industry has seen in five years, driven by an unusual combination of record dealmaking firepower, a compressed patent cliff timeline, and a Chinese biotech ecosystem that is now sourcing a meaningful share of Western pharma pipelines. Aggregate biopharma M&A reached $133 billion in 2025, more than doubling from 2024 levels, and IQVIA forecasts deal value of $140 billion to $160 billion in 2026 with potential upside of $20 billion to $30 billion in a best-case scenario. PwC’s US Pharma and Life Sciences Deals Leader Roel van den Akker has framed 2026 as the year capital meets opportunity, with Goldman Sachs going further and predicting a record-breaking year for pharma and biotech M&A. The first quarter has already delivered $15.6 billion across 19 biopharma transactions according to J.P. Morgan data, with the late-March surge alone producing seven deals worth a combined $29 billion.

The headline question for the rest of 2026 is no longer whether dealmaking will accelerate. It is whether the largest acquirers can deploy capital fast enough to offset what is shaping up as the steepest revenue exposure event in pharmaceutical history.

What is driving the surge in pharma M&A activity in 2026 and how does it compare to previous cycles

Three forces are converging simultaneously. The first is balance sheet capacity. EY Americas life sciences leader Arda Ural has put the firepower value of the top 25 pharmaceutical companies at $1.3 trillion, one of the highest absolute readings on record. IQVIA’s separate estimate aligns with this figure, noting that despite the 2025 rebound, much of the available dry powder remains uncommitted. This is not the cyclical capital availability of 2019 or 2021. It reflects a sustained period of cash generation by GLP-1 leaders, oncology franchise holders, and immunology incumbents who have under-invested in M&A through the rate-hike cycle.

The second force is the patent cliff itself. IQVIA’s analysis identifies more than $230 billion in biopharma revenue facing loss-of-exclusivity exposure by 2030, with up to 65 percent of certain large-cap pharma sales at risk. Keytruda, Gardasil, Eliquis, Jardiance, Opdivo, Darzalex, and Cosentyx all face exclusivity erosion within the window. A second wave is expected to expose another $200 billion to $250 billion of industry revenue in the early 2030s. Merck’s Keytruda alone generated more than $30 billion in 2025 and faces generic competition from 2028. The compression of these timelines has changed the calculus for portfolio strategy from opportunistic to defensive, and the M&A market is responding accordingly.

The third force is the Chinese biotech pipeline. Evaluate director Mark Lansdell has reported that deals involving Chinese pharma and biotech firms reached $92.2 billion in potential value through November 2025, nearly double the $51.9 billion recorded in 2024. EY’s Arda Ural estimates that approximately 35 percent of the deals announced in 2025 originated in China. The reasoning is mechanical rather than ideological. Chinese biotechs can move assets to first-in-human status faster and at lower cost, and in 2024 China overtook the United States in oncology trial volumes, conducting 39 percent of global oncology trials versus 32 percent in the US.

Which therapeutic areas are attracting the highest pharma M&A deal values in 2026

Oncology, neuroscience, obesity, and cardiometabolic disease are the four areas absorbing the bulk of meaningful capital. The Q1 2026 transaction set illustrates the pattern. Merck announced a $6.7 billion all-cash acquisition of Terns Pharmaceuticals on 25 March 2026, paying $53 per share for an oncology-focused biotech whose lead asset TERN-701 is an oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia. The transaction is Merck’s third multibillion-dollar acquisition over the prior twelve months, following its $9.2 billion Cidara Therapeutics deal and $10 billion Verona Pharma acquisition completed in 2025. Merck has been explicit about its strategy: chairman and chief executive Robert Davis has stated the company is targeting $70 billion in annual sales next decade and is using M&A and internal research progression to reach that goal.

Six days later, on 31 March 2026, Eli Lilly announced a definitive agreement to acquire UK-based Centessa Pharmaceuticals for $6.3 billion upfront, with up to $1.5 billion in additional contingent value right payments tied to FDA approvals before 2030. The acquisition centres on Centessa’s orexin receptor 2 agonist pipeline, with lead candidate cleminorexton positioned for narcolepsy and idiopathic hypersomnia. Oppenheimer analyst Kostas Biliouris has estimated the orexin agonist market at $15 billion to $20 billion if even one-quarter of patients with narcolepsy and idiopathic hypersomnia seek treatment. The Centessa transaction represents a 38 percent premium to the prior closing price and follows Eli Lilly’s January 2026 acquisition of Ventyx Biosciences for $1.2 billion in inflammatory disease assets.

The contrast in deal economics across these transactions reveals how acquirers are pricing different scarcities. Merck’s Terns deal carried only a 6 percent purchase premium, among the lowest paid for a publicly traded drugmaker since 2018 according to BioPharma Dive data, and Leerink Partners analyst Andrew Berens has argued the price vastly underestimates TERN-701’s potential. The structure suggests Merck won a competitive process at a price that other large pharmaceutical bidders were reluctant to match, possibly because of capital allocation constraints or competing oncology priorities. Eli Lilly, by contrast, paid a substantial premium for Centessa because orexin agonist competition is consolidating around three or four serious developers, and Takeda’s oveporexton is already under FDA review.

How is the China biotech pipeline reshaping global pharma deal flow in 2026

The structural shift in cross-border pharmaceutical dealmaking is the single most underappreciated trend in the 2026 outlook. PwC’s deals analysis identifies China-to-the-West licensing and co-development as a core vector in corporate development strategies, with Western pharma using structured licenses, regional development rights, and contingent financial tools to access Chinese innovation while managing intellectual property and supply chain risks. The pattern has moved beyond opportunistic licensing into systematic pipeline sourcing.

The implications cut multiple ways. For Western biotechs, Chinese-origin assets represent direct competition for big pharma attention and capital, particularly in oncology where Chinese trial infrastructure is now superior in throughput. For policy makers in Washington, Brussels, and London, the dependency raises the same supply chain and intellectual property questions that have driven semiconductor and critical minerals policy over the past three years. EY’s Arda Ural has flagged the most-favored-nation drug pricing policy as a complicating factor that may cause acquirers to hesitate on certain licensing structures with Chinese counterparties.

What does the 2026 patent cliff mean for big pharma capital allocation strategy

The capital allocation question is sharper than it appears in headline coverage. With $1.3 trillion in dealmaking capacity across the top 25 large-cap pharmaceutical companies and $230 billion in revenue facing exclusivity loss by 2030, the implied replacement cost per dollar of revenue is theoretically manageable. The constraint is not capital. It is the supply of differentiated, late-stage clinical assets at scale.

IQVIA’s analysis suggests acquirers will continue exercising strict capital discipline with sharp therapeutic focus, favouring bolt-on acquisitions in the $5 billion to $10 billion range, with $10 billion-plus transactions reserved for prime targets where strategic fit is clear. Mega-mergers are expected to remain the rare exception given the chequered track record of large pharmaceutical combinations and the operational complexities of integrating two large entities. The implication is that the deal flow will continue at high frequency rather than concentrating in a small number of transformational transactions, which favours small and mid-cap biotechs with single high-quality assets over diversified platform companies.

Private equity is increasingly active in pharmaceutical services and pharmaceutical technology, with structured financing, royalty deals, and minority interests bridging late-stage development to commercialisation. PwC’s deals practice expects this to continue through 2026, particularly for emerging biopharma companies that now represent 70 percent of all clinical-stage assets but face a venture capital environment that fell below historical averages in 2025.

What are the biggest risks to the 2026 pharma M&A outlook

Three risks merit closer attention than they typically receive. The first is regulatory unpredictability around the most-favored-nation drug pricing framework, which Ural has identified as already affecting licensing deal calculus. A binding implementation could compress US revenue projections enough to alter acquisition models, particularly for assets with US-heavy commercial profiles. The second is integration execution. Merck has now completed three large oncology acquisitions in twelve months while simultaneously dividing its human health business into separate oncology and infectious disease divisions. The cumulative integration burden is substantial, and any visible execution failure would chill the broader M&A environment. The third is valuation discipline. The Terns transaction’s 6 percent premium has already triggered analyst speculation that AbbVie or Bristol Myers Squibb might top Merck’s offer, and a competing bid would signal a shift toward premium-paying behaviour that would re-rate the entire small-cap biotech universe.

A reasonable base case for 2026 is the IQVIA range of $140 billion to $160 billion in aggregate deal value, weighted toward Q2 and Q3 announcements, with bolt-on transactions of $5 billion to $10 billion dominating headline volume. The bear case is a regulatory shock that compresses US pricing and pauses the Chinese deal vector simultaneously. The bull case, consistent with Goldman Sachs’s record-year forecast, would require both the resolution of MFN policy uncertainty and at least one mega-deal returning to the table, which neither IQVIA nor PwC currently flags as their central scenario.

What are the key takeaways from pharma M&A trends in 2026

• Big pharma firepower across the top 25 companies stands at $1.3 trillion according to EY estimates, the highest readings on record, providing structural deal capacity for multiple years of activity
• IQVIA forecasts aggregate biopharma M&A deal value of $140 billion to $160 billion in 2026, with Goldman Sachs predicting a record-breaking year and PwC framing the environment as capital meeting opportunity
• The patent cliff exposes more than $230 billion in revenue to loss-of-exclusivity by 2030, including Keytruda, Gardasil, Eliquis, Jardiance, Opdivo, Darzalex, and Cosentyx, with a second wave of $200 to $250 billion exposed in the early 2030s
• Q1 2026 saw 19 biopharma deals worth $15.6 billion, with seven late-March transactions alone reaching $29 billion in combined value
• Merck’s $6.7 billion acquisition of Terns Pharmaceuticals at a 6 percent premium has reset analyst expectations on oncology bolt-on pricing and triggered speculation about competing bids from AbbVie or Bristol Myers Squibb
• Eli Lilly’s $6.3 billion Centessa Pharmaceuticals acquisition with $1.5 billion in contingent value rights signals that orexin agonist competition has consolidated and that Eli Lilly is willing to pay full premiums for category leadership
• Chinese biotech transactions reached $92.2 billion in potential value through November 2025 and accounted for approximately 35 percent of all deals announced that year, driven by faster trial timelines and dominant oncology trial infrastructure
• Bolt-on acquisitions in the $5 billion to $10 billion range will dominate 2026 deal flow, with mega-mergers remaining the rare exception due to integration complexity and the chequered track record of large pharmaceutical combinations
• Most-favored-nation drug pricing policy and integration execution at acquirers like Merck represent the principal downside risks to the 2026 outlook
• Emerging biopharma companies now represent 70 percent of all clinical-stage assets, and the combination of weak 2025 venture capital and limited IPO recovery is forcing smaller biotechs toward M&A as a primary capital strategy